Adicet Bio (ACET) Investor presentation summary

Pipeline overview and development strategy

• Advancing allogeneic yō1 T cell therapies for autoimmune diseases and cancer, with prula-cel targeting CD20 for multiple autoimmune indications and ADI-212 targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC).

• Prula-cel is being developed for lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSC), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS), anti-neutrophil cytoplasmic autoantibody vasculitis (AAV), and rheumatoid arthritis (RA).

• ADI-212 is a next-generation, gene-edited, armored CAR T cell therapy for mCRPC, with regulatory filing planned for 3Q 2026 and enrollment initiation in 4Q 2026.

• Early-stage programs include in vivo CAR T and yō CAR T for autoimmune, hematological malignancies, and solid tumors.

• Key upcoming milestones include multiple clinical updates and pivotal study initiations in 2H 2026.

Prula-cel clinical data and impact

• Phase 1 data show prula-cel is well tolerated with no ≥Gr2 cytokine release syndrome (CRS) or ICANS, supporting outpatient administration.

• All patients (5 LN, 2 SLE) achieved rapid, sustained reductions in disease activity and discontinued immunosuppressants; most discontinued or tapered corticosteroids to physiological levels.

• Improved kidney function observed in all LN patients, with three complete and two partial renal responses.

• Evidence of immune reset with emergence of naïve B cell repertoire and depletion of dominant, potentially pathogenic B cell clones.

• Off-the-shelf availability eliminates need for leukapheresis and manufacturing delays.

Safety and comparative tolerability

• Prula-cel demonstrated a favorable safety profile compared to autologous CAR-T therapies, with lower rates of CRS, ICANS, and infections.

• No cases of graft-versus-host disease, HLH-MAS, or prolonged neutropenia were reported.

• Safety profile supports outpatient dosing and potential for one-time therapy.